Sergey Mavrichev
N.N. Alexandrov National Cancer Centre of Belarus, BelarusTitle: The use of treosulfan in combination with irinotecan in treatment of platinum-resistant ovarian cancer
Abstract
Actuality: Ovarian cancer occupies the first place in the structure of mortality of diseases of the reproductive sphere of women. Despite of high sensitivity of the tumor to the 1st line of therapy 10% of patients get progression disease during treatment with platinum and 70% of patients get progression on first two years after the treatment. According to the literature, while using the second line of chemotherapy of ovarian cancer, the tumor response rate of the treatment is on average 15-25%. Progression-free survival (PFS) is 3-4 months, the overall survival (OS) of these patients is 6-8 months.
Materials and methods: At the N.N. Alexandrov National Cancer Centre of Belarus 152 patients with platinum-resistant ovarian cancer were treated with treosulfan at a dose of 6 g/m2 in combination with irinotecan at a dose of 180 mg/m2 on day 1. The interval between courses was 21 days.
Results: In total of 791 courses of treatment were carried out. A complete tumor response to therapy was registered in 11 patients (7.2%), a partial response – in 56 patients (36.8%), stabilization of the tumor process – in 41 patients (27.0%). The median time of progression was 6.63 month, and the median of overall survival was 16.9 month. Grade III–IV of neutropenia occurred in 7.8%, grade III–IV anemia– in 1.9%, grade III–IV thrombocytopenia– in 0.5%. Another side effects were isolated.
Conclusion: Thus, the combined use of treosulfan with irinotecan has shown a sufficiently high efficacy, an acceptable level of toxicity and can be recommended as a therapy for platinum-resistant ovarian cancer.
Biography
WILL BE UPDATED SOON
Organization Location
1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801, USA
Mail us at
Program Enquiry
gynaecology@scientexconferences.com
General Enquiry
contact@scientexconferences.com
Registration query
finance@scientexconferences.com
gynaecology@scientexevents.org
Our Social Presence
Call us at
USA :(+1) 202 773 8420